anti-cd47

Magrolimab (Hu5F9-G4) is a humanized anti-CD47 IgG4 monoclonal antibody that exhibits antitumor activity by blocking CD47 and binding primarily to the N-terminal pyroglutamate of CD47. It can be used in combination with other compounds for the treatment of recurrent myeloma.

Anti-CD47 Antibody (B6.H12) is a chimeric mouse IgG1 κ antibody that specifically targets human CD47. The recommended isotype control for Anti-CD47 Antibody (B6.H12) is Mouse IgG1 kappa, Isotype Control.

Anti-CD47 (A4) antibody is a kind of antibody that can be used for Blocking, functional assays, FC and other related research.

Anti-CD47 (h4C1) antibody is a kind of antibody that can be used for Block, ELISA, FC and other related research.

Anti-Mouse CD47 IAP Antibody (MIAP301) is an IgG2a, κ antibody inhibitor derived from rats that targets mouse CD47 IAP.

Anti-Mouse Rat Human CD47 IAP Antibody (MIAP410) is a mouse-derived IgG1, κ antibody inhibitor targeting CD47 IAP in mice, rats, and humans.

Anti-human mouse CD47 (VxP037-01LC1) antibody is a kind of antibody that can be used for blocking and other related research.

CC-90002, a humanized anti-CD47 monoclonal antibody (mAb), demonstrates high affinity for CD47, characterized by a subnanomolar dissociation constant (K d). It is utilized in the research of hematologic malignancies and solid tumors [1] [2].

Ligufalimab (AK 117), a humanized IgG4 monoclonal antibody targeting CD47, does not lead to red blood cell (RBC) hemagglutination but promotes phagocytosis and exhibits anti-tumor activity [1].

Lemzoparlimab (TJ011133) is a differentiated anti-CD47 humanized antibody with anti-tumor activity, used in the study of myeloid leukemia.

Anzurstobart (CC-95251; BMS-986351), a fully human monoclonal anti-SIRPα antibody with high affinity, inhibits the CD47-SIRPα interaction, potentiates macrophage-mediated phagocytosis of DLBCL cell lines in co-culture assays with Rituximab, and shows promise in solid and hematologic malignancy research [1].

STI-6643 is a fully human IgG4 antibody that targets and binds to CD47. It exhibits potent anti-tumor activity with negligible toxicity towards red blood cells and lymphocytes. The isotype control for STI-6643 can be referenced as HumanIgG4(S228P) kappa, Isotype Control.